Researchers found targeting androgens/AR with either the recently developed antiandrogen Enzalutamide or AR-shRNAs led to increased prostate cancer cell invasion, yet decreased bladder cancer cell invasion.
[Cell Death & Differentiation]
Sorry, but the selected Zotpress account can't be found.